Latest ArticlesDiabetic kidney disease (DKD) is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD), and CKD is closely related to dyslipidemia and ectopic lipid deposition (ELD). Previous studies have shown that hyperlipidemia can lead to the occurrence and progression of CKD, as well as DKD. Lipid regulating drugs can improve the renal prognosis of patients with type 2 diabetes mellitus (T2DM). Hyperglycemia, hypertriglyceridemia and low high density lipoprotein-cholesterol may play important roles in the development of DKD. Therefore, the relationship between abnormal lipid metabolism and DKD was discussed, and the potential mechanism of DKD lipid induced renal damage was analyzed to provide some reference for clinical diagnosis and treatment.
Sjögren syndrome (SS) is a chronic autoimmune disease characterized by destruction of exocrine glandular epithelium and severe drying of mucosal surface, with complex etiology. It is difficult to diagnose SS accurately because of its extensive manifestations and overlapping of signs and symptoms with other autoimmune diseases. At present, substitution and symptomatic treatment are mainly used in clinic to delay the disease and improve symptoms, but the effect is often not ideal, and there is no radical cure. In recent years, with the continuous development of various targeted drugs, some new theatments and means have emerged in the clinical treatment of SS. This article reviewed the therapeutic drugs of SS in recent years in order to provide reference for clinical medication.
Corona virus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are spreading globally on a large scale, threatening the safety of human life seriously, and the world needs effective drugs against COVID-19 urgently. Recently, four oral small molecule drugs have been successfully approved for market to treat patients with early mild COVID-19, they were 3C-like protease (3CLpro) inhibitor, RNA-dependent RNA polymerase (RdRp) inhibitor, monoclonal antibody, androgen receptor inhibitor. This paper briefly summarizes these four types of drugs and reviews their clinical therapeutic effects, characteristics and mechanism of action, to provide some references for the development and usage of drugs for the treatment of COVID-19.
With the development of drug clinical trials, investigator-initiated trial (IIT) plays an increasingly important role. This paper analyzed the management modes of drug clinical trial and IIT, and compared the differences of management modes between drug clinical trial and IIT, in order to provide reference for the construction of IIT management system in China.
Prostaglandin E2 has the function of dilating blood vessels and soothing smooth muscles, and has been found to play an important role in the repair of gastrointestinal mucosal wounds. Cyclooxygenase is the main synthetase of prostaglandin (PG)E2, and prostaglandin transporter and 15-hydroxyprostaglandin dehydrogenase are the main metabolic proteins. In this paper, the role of PGE2, cyclooxygenase, prostaglandin transporter and 15-hydroxyprostaglandin dehydrogenase in wound repair were reviewed to explore the characteristics of wound repair with PGE2 as the core, so as to provide some ideas and means for selecting better drug targets to promote wound repair in the future.
Patients with heart failure (HF) have a higher risk of death, and diabetes mellitus (DM) is an important risk factor for HF. Sodium-glucose linked transporter 2 (SGLT2) inhibitor, as a new anti-hyperglycemia drug in recent years, has been proved to prevent cardiovascular events and improve the prognosis of patients with HF with reduced ejection fraction (HFrEF), and reduce the risk of HF hospitalization and cardiovascular death. This benefit is consistent in patients with or without DM. This article reviewed the previous literature on the effects of SGLT2 inhibitors on cardiovascular outcomes, especially on HF, in order to provide references for clinical medication.
Dyslipidemia, characterized by elevated low density lipoprotein-cholesterol (LDL-C), is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a class of compounds that inhibit PCSK9 and are a class of new lipid-lowering drugs. It interferes with the recycling of low density lipoprotein receptor (LDLR), thus hindering LDL-C clearance mediated by LDLR, which brings new hope for lipid-lowering therapy. This article reviewed the discovery, structure, regulation and biological functions of PCSK9 targets, focusing on the pharmacodynamics, pharmacokinetics and recent clinical research progress of monoclonal antibodies and small interfering RNA drugs, in order to provide reference for clinical diagnosis and treatment.
Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a new class of anti-diabetes mellitus (DM) drugs. SGLT2 is usually involved in the reabsorption of about 90% of the glucose filtered by the glomerular. SGLT2 inhibitors directly reduce blood sugar by inhibiting the active transport of glucose by SGLT2, inhibiting the reabsorption of glucose by the kidneys, increasing urinary glucose excretion. SGLT2 inhibitors are becoming increasingly important in the treatment of type 2 DM (T2DM), as they can not only reduce blood glucose, but also have cardio-renal protective effects. SGLT2 inhibitors have been widely used after being marketed in China. Now, the pharmacokinetic characteristics, hypoglycemic effect, cardiovascular protection, renal protection and adverse reactions of SGLT2 inhibitors that have been listed in China were compared in order to provide reference for clinical medication.
Pharmacoeconomic evaluation is an important tool for drug access and pricing decisions. The results of pharmacoeconomic evaluation carried out under different perspectives are different due to different costs and health outcomes they cover. However, the research perspective that should be adopted for the pharmacoeconomic evaluation to support the adjustment decision of the national reimbursement drug list in China (except Hong Kong, Macao and Taiwan) has not been clearly defined. Based on the submission guidelines of typical countries and regions, this paper analyzed the characteristics and applicable scenarios of different perspectives, and suggested that in China (except Hong Kong, Macao and Taiwan), started from the positioning of basic medical insurance system, the baseline analysis should be conducted from the perspective of basic medical insurance payers, and supplementary analysis should be conducted from other appropriate perspectives. Besides, the costs and health outcomes that should be included in the assessment under the corresponding perspective need to be specified in the submission guidelines.